MYOV

Myovant Sciences Ltd. [MYOV] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

MYOV Stock Summary

Earnings have grown 289.39% per last year.

Earnings are expected to rise 63.93% next year

EPS has been increasing for the past 3 years (Yearly statements)

EPS has been decreasing for the past 3 quarters (Quarter statements)

Currently unprofitable, and not expected to turn profitable in the coming year

In the News

06:48 22 Mar 2023 MYOV

Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue Estimates

Myovant Sciences (MYOV) delivered earnings and revenue surprises of -5.36% and 3.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

11:19 22 Mar 2023 MYOV

Myovant Sciences (MYOV) Reports Q2 Loss, Tops Revenue Estimates

Myovant Sciences (MYOV) delivered earnings and revenue surprises of 4.08% and 13.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

11:29 22 Mar 2023 MYOV

Why Sumitomo Pharma Is Buying Myovant Sciences (MYOV) For $2.9 Billion

Sumitovant Biopharma recently announced it is buying Myovant Sciences (MYOV) in a $2.9 billion deal. This is why.

04:30 22 Mar 2023 MYOV

Myovant Sciences Cancels Second Quarter Earnings Conference Call

BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time. The call is being cancelled due to the announcement of the pending merger with Sumitovant Biopharma Ltd.

11:23 22 Mar 2023 MYOV

MYOV Stock Pops as Sumitomo Agrees to Buy Myovant Sciences

Today's market-moving news in the drugmaker sector is that Sumitomo Pharma and a subsidiary have agreed to buy out the remainder of Myovant Sciences (NYSE: MYOV ) that they don't already own. Furthermore, they raised their offer to make this purchase.

09:36 22 Mar 2023 MYOV

Why Myovant Sciences Stock Is Moving Higher - Myovant Sciences (NYSE:MYOV)

Myovant Sciences Ltd (NYSE: MYOV) shares are trading higher Monday after the company announced it will be acquired by Sumitovant Biopharma for $27 per share in cash.

08:12 22 Mar 2023 MYOV

Myovant Sciences shares trading higher after agreeing to Sumitomo deal for $2.9 billion

Shares of Myovant Sciences Ltd. MYOV, +0.95% were up 8.2% in premarket trading on Monday, the day after the company said it will be acquired by Sumitomo Pharma Co. Ltd.

06:45 22 Mar 2023 MYOV

Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.

BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022. The webcast and conference call will be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on October 26, 2022.

06:44 22 Mar 2023 MYOV

Myovant Sciences: What The Sumitomo Offer Foretells

As Myovant overcame the odds as I forecast, Myfembree garnered another FDA approval to treat endometriosis. Subsequent to the said game-changing event, Sumitomo made an offer to acquire all outstanding shares at $22.75. However, Myovant's Board rejected the offer.

02:34 22 Mar 2023 MYOV

Myovant: Sumitomo Bid Is A Head Scratcher, Where Is The Value?

Myovant stock has rocketed in value by >100% since my last (bearish) note on the company. The main reason for the Myovant gains is an attempt by majority shareholder Sumitomo to acquire remaining shares for $22.75 per share.

MYOV Financial details

Company Rating

Neutral

Market Cap

2.62B

Income

-183.77M

Revenue

379.11M

Book val./share

-5.76

Cash/share

2.83

Dividend

Dividend %

Employees

579

Optionable

Shortable

Yes

Earnings

08 May 2023

P/E

-14.22

Forward P/E

PEG

4.37

P/S

6.89

P/B

-4.68

P/C

9.53

P/FCF

-9.69

Quick Ratio

1.3

Current Ratio

1.57

Debt / Equity

-1.72

LT Debt / Equity

-0.65

EPS (TTM)

-1.91

EPS next Y

EPS next Q

-0.56

EPS this Y

-21.55%

EPS next Y

EPS next 5Y

26.96%

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

-4.38%

EPS Q/Q

25.53%

SMA20

0.3%

SMA50

0.22%

SMA100

8.71%

Inst Own

43%

Inst Trans

13.45%

ROA

-46%

ROE

36%

ROC

-0.93%

Gross Margin

73%

Oper. Margin

-39%

Profit Margin

-48%

Payout

Shs Outstand

97.26M

Shs Float

50.86M

Target Price

52W Range

7.67-27.06

52W High

-0.07%

52W Low

+285.43%

RSI

61.04

Rel Volume

2.07

Avg Volume

1.07M

Volume

2.21M

Perf Week

0.07%

Perf Month

0.3%

Perf Quarter

Perf Half Y

44.82%

Beta

2.15468

Volatility

0.01%, 0.04%

Prev Close

-0.04%

Price

26.98

Change

0.04%

MYOV Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-03-31

Metric	2018-03-31	2019-03-31	2020-03-31	2021-03-31	2022-03-31
Revenue per share	0	0	0	0.66	2.48
Net income per share	-2.41	-4.09	-3.37	-2.83	-2.22
Operating cash flow per share	-1.97	-3.35	-2.58	4.12	-2.89
Free cash flow per share	-1.98	-3.37	-2.59	4.1	-2.9
Cash per share	1.82	2.33	0.93	7.61	4.67
Book value per share	0.63	0.06	-1.26	-3.93	-5.09
Tangible book value per share	0.63	0.06	-1.26	-3.93	-5.09
Share holders equity per share	0.63	0.06	-1.26	-3.93	-5.09
Interest debt per share	0.77	1.62	1.47	4.22	4.11
Market cap	1.27B	1.59B	648.09M	1.85B	1.24B
Enterprise value	1.2B	1.53B	688.14M	1.55B	1.2B
P/E ratio	-8.84	-5.81	-2.24	-7.26	-6.01
Price to sales ratio	0	0	0	31.24	5.36
POCF ratio	-10.8	-7.1	-2.93	5	-4.61
PFCF ratio	-10.74	-7.06	-2.92	5.02	-4.59
P/B Ratio	33.56	366.97	-5.99	-5.23	-2.62
PTB ratio	33.56	366.97	-5.99	-5.23	-2.62
EV to sales	0	0	0	26.1	5.19
Enterprise value over EBITDA	-8.53	-5.81	-2.51	-6.4	-6.52
EV to operating cash flow	-10.24	-6.84	-3.11	4.18	-4.47
EV to free cash flow	-10.19	-6.81	-3.1	4.2	-4.45
Earnings yield	-0.11	-0.17	-0.45	-0.14	-0.17
Free cash flow yield	-0.09	-0.14	-0.34	0.2	-0.22
Debt to equity	2.16	38.91	-1.98	-3.05	-2.1
Debt to assets	0.68	0.97	2.02	1.49	1.91
Net debt to EBITDA	0.46	0.21	-0.15	1.26	0.21
Current ratio	3.09	2.32	1.02	2.5	1.95
Interest coverage	-68.95	-30.02	-21.71	-25.07	-13.41
Income quality	0.82	0.82	0.77	-1.45	1.3
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	2.3	0.47
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0.01	0	0	0
Capex to revenue	0	0	0	-0.03	0
Capex to depreciation	-2.49	-2.82	-0.62	-0.72	-0.32
Stock based compensation to revenue	0	0	0	0.9	0.17
Graham number	5.86	2.44	9.77	15.83	15.93
ROIC	1.38	1.77	4.4	0.41	0.63
Return on tangible assets	-1.2	-1.58	-2.73	-0.35	-0.4
Graham Net	0.47	-0.18	-1.57	-4.33	-5.78
Working capital	77.68M	94.82M	1.99M	423.31M	237.82M
Tangible asset value	37.73M	4.33M	-108.28M	-353.97M	-473.48M
Net current asset value	33.39M	-1.85M	-126.29M	-374.35M	-505.34M
Invested capital	1.16	22.93	-1.05	-1.04	-0.78
Average receivables	500K	762K	262K	1.79M	13.72M
Average payables	2.29M	7.8M	13.18M	16.57M	15.03M
Average inventory	0	0	0	1.31M	5.1M
Days sales outstanding	0	0	0	21.97	37.73
Days payables outstanding	0	0	0	3.31K	86.73
Days of inventory on hand	0	0	0	484.99	53.7
Receivables turnover	0	0	0	16.62	9.67
Payables turnover	0	0	0	0.11	4.21
Inventory turnover	0	0	0	0.75	6.8
ROE	-3.8	-63.12	2.67	0.72	0.44
Capex per share	-0.01	-0.02	-0.01	-0.02	-0.01

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q3

Metric	2021-12-31	2022-03-31	2022-06-30	2022-09-30	2022-12-31
Revenue per share	0.58	0.62	1.22	1.09	1.03
Net income per share	-0.68	-0.63	-0.22	-0.47	-0.59
Operating cash flow per share	-0.98	-1.07	-0.8	0.09	-1.06
Free cash flow per share	-0.99	-1.07	-0.8	0.09	-1.06
Cash per share	5.65	4.64	3.74	3.86	2.83
Book value per share	-4.62	-5.07	-5.07	-5.33	-5.76
Tangible book value per share	-4.62	-5.07	-5.07	-5.33	-5.76
Share holders equity per share	-4.62	-5.07	-5.07	-5.33	-5.76
Interest debt per share	3.98	3.97	3.9	3.86	3.85
Market cap	1.46B	1.25B	1.19B	1.73B	2.61B
Enterprise value	1.37B	1.21B	1.23B	1.75B	2.73B
P/E ratio	-5.73	-5.25	-13.96	-9.47	-11.33
Price to sales ratio	26.73	21.63	10.18	16.48	26.05
POCF ratio	-15.84	-12.44	-15.6	189.47	-25.38
PFCF ratio	-15.78	-12.41	-15.59	196.22	-25.32
P/B Ratio	-3.37	-2.63	-2.45	-3.37	-4.68
PTB ratio	-3.37	-2.63	-2.45	-3.37	-4.68
EV to sales	25.09	20.95	10.54	16.72	27.21
Enterprise value over EBITDA	-23.19	-23.63	-151.92	-54.98	-55.19
EV to operating cash flow	-14.87	-12.05	-16.15	192.2	-26.51
EV to free cash flow	-14.81	-12.02	-16.14	199.05	-26.45
Earnings yield	-0.04	-0.05	-0.02	-0.03	-0.02
Free cash flow yield	-0.06	-0.08	-0.06	0.01	-0.04
Debt to equity	-2.4	-2.1	-1.95	-1.94	-1.72
Debt to assets	1.72	1.91	2.05	2.06	2.38
Net debt to EBITDA	1.52	0.76	-5.18	-0.78	-2.35
Current ratio	2.14	1.95	1.89	1.83	1.57
Interest coverage	-17.17	-14.87	-2.23	-7	-8.48
Income quality	1.45	1.69	3.58	-0.2	1.79
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.47	0.43	0.21	0.26	0.31
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	-0.03	0
Capex to revenue	-0.01	0	0	0	0
Capex to depreciation	-0.47	-0.33	-0.09	-0.39	-0.26
Stock based compensation to revenue	0.13	0.15	0.08	0.11	0.11
Graham number	8.4	8.5	5.04	7.54	8.78
ROIC	0.19	0.18	0.08	0.2	0.48
Return on tangible assets	-0.1	-0.11	-0.05	-0.09	-0.14
Graham Net	-5.25	-5.75	-5.8	-6.12	-6.6
Working capital	305.72M	237.82M	200.59M	209.22M	140.83M
Tangible asset value	-432.28M	-473.48M	-483.52M	-513.25M	-558.14M
Net current asset value	-461.82M	-505.34M	-516.83M	-536.31M	-575.08M
Invested capital	-0.85	-0.78	-0.76	-0.71	-0.66
Average receivables	16.93M	21.67M	26.99M	32.41M	39.36M
Average payables	10.39M	12.19M	10.9M	8.88M	10.22M
Average inventory	6.44M	7.16M	14.4M	22.13M	26.57M
Days sales outstanding	32.17	37.33	23.26	29.8	39.53
Days payables outstanding	66.86	62.14	37.49	27.02	32.13
Days of inventory on hand	37.13	38.47	83.29	75.81	79.11
Receivables turnover	2.8	2.41	3.87	3.02	2.28
Payables turnover	1.35	1.45	2.4	3.33	2.8
Inventory turnover	2.42	2.34	1.08	1.19	1.14
ROE	0.15	0.13	0.04	0.09	0.1
Capex per share	0	0	0	0	0

MYOV Frequently Asked Questions

What is Myovant Sciences Ltd. stock symbol ?

Myovant Sciences Ltd. is a GB stock and trading under the symbol MYOV

What is Myovant Sciences Ltd. stock quote today ?

Myovant Sciences Ltd. stock price is $26.98 today.

Is Myovant Sciences Ltd. stock public?

Yes, Myovant Sciences Ltd. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Same Price Range

Similar Market Cap

Company Profile

Volume Average 1.07M
Market Capitalization 2.62B
Employee 579
CEO Mr. David C. Marek
Headquarters London,GB
IPO Date 2016-10-27
Website https://myovant.com

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.